Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8778393 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
US9320710 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
US10342762 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
US8231900 | ACELRX PHARMS | Small-volume oral transmucosal dosage |
Jan, 2027
(3 years from now) | |
US8252328 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
US9744129 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
US8252329 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
US8226978 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
US8865211 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
US10245228 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
US10507180 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
US8535714 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
US8778394 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
US8574189 | ACELRX PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(6 years from now) | |
US10896751 | ACELRX PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(6 years from now) | |
US8202535 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Oct, 2030
(7 years from now) | |
US8865743 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Oct, 2030
(7 years from now) | |
US8945592 | ACELRX PHARMS | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
Jul, 2031
(8 years from now) |
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET;SUBLINGUAL
45
United States
11
European Union
10
Japan
9
China
8
Korea, Republic of
8
Canada
6
Spain
5
Denmark
4
Portugal
1
Israel
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Germany
1
Singapore
1
Brazil
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic